TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

XELLIA PHARMS APS

Infectious DiseaseDermatology
Generics

XELLIA PHARMS APS is a generic drug manufacturer focused on Infectious Disease, Dermatology. Key products include CASPOFUNGIN ACETATE.

2014
Since
8
Drugs
-
Trials
46
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

MICAFUNGIN SODIUM 2026-02-24
DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
MICAFUNGIN SODIUM 2026-01-21
VANCOMYCIN HYDROCHLORIDE 2025-10-02
DAPTOMYCIN 2025-08-08
Labeling
TIGECYCLINE 2025-08-06
Labeling
MICAFUNGIN SODIUM 2025-07-23
Labeling
CASPOFUNGIN ACETATE 2025-07-18
POLYMYXIN B SULFATE 2025-07-03
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 67%
6 drugs
Dermatology 33%
3 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology
COSETTE other
Dermatology, Infectious Disease
BAUSCH AND LOMB specialty
Infectious Disease, Dermatology